Conversely, there is increasing interest in the possible therapeutic benefits of blocking CTLA4 (using antagonistic antibodies against CTLA such as ipilimumab (FDA approved for melanoma in 2011) as a means of inhibiting immune system tolerance to tumours and thereby providing a potentially useful immunotherapy strategy for patients with cancer.
Inversamente, hai un crecente interese nos posibles beneficio terapéuticos de bloquear o CTLA4 (usando anticorpos antagonistas contra o CTLA, como ipilimumab (aprobado pola FDA norteamericana para o melanoma en 2011) como medio para inhibir a tolerancia do sistema inmunitario a tumores e servir de estratexia de inmunoterpia potencialmente útil para pacientes con cancro.